Rossig Claudia
University Children's Hospital Muenster, Pediatric Hematology & Oncology, Albert-Schweitzer Campus 1, Building A1, 48149 Muenster, Germany.
Immunotherapy. 2014;6(5):611-21. doi: 10.2217/imt.14.36.
Ewing sarcoma is a rare cancer of bone and soft tissues defined by a specific chromosomal rearrangement. Preclinical development of immunological treatment strategies includes expansion of T cells with native or grafted T-cell receptor specificities for Ewing sarcoma-associated intracellular antigens, and T-cell engineering with chimeric antigen receptors targeting surface antigens. In vitro preactivated NK cells may also have activity in this cancer. Major challenges are the heterogeneity of antigen expression in individual Ewing sarcomas, and the coexpression of most candidate targets on normal cells. Moreover, homing of therapeutic effector cells to both primary and metastatic tumor sites and adequate function within the immunosuppressive tumor microenvironment will have to be ensured to allow for effective immune targeting of this cancer.
尤因肉瘤是一种罕见的骨与软组织癌症，由特定的染色体重排所定义。免疫治疗策略的临床前开发包括扩增对尤因肉瘤相关细胞内抗原具有天然或移植T细胞受体特异性的T细胞，以及用靶向表面抗原的嵌合抗原受体进行T细胞工程改造。体外预激活的自然杀伤细胞在这种癌症中也可能具有活性。主要挑战在于个体尤因肉瘤中抗原表达的异质性，以及大多数候选靶点在正常细胞上的共表达情况。此外，必须确保治疗效应细胞归巢至原发性和转移性肿瘤部位，并在免疫抑制性肿瘤微环境中具备充分功能，以便对这种癌症进行有效的免疫靶向治疗。
